5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion

Psychopharmacology
Catharine A WinstanleyTrevor W Robbins

Abstract

Global serotonin (5-HT) depletion increases the number of premature responses made on the five-choice serial reaction time task (5CSRT) in rats. In contrast, the 5-HT(2A) receptor antagonist M100907 decreases this measure of impulsivity. Mounting evidence suggests that 5-HT(2A) and 5-HT(2C) receptors have opposing effects on behaviour, and that the 5-HT(2C) receptor antagonist SB 242084 produces a pattern of behaviour similar to 5-HT depletion. To assess the effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on performance of the 5CSRT, to directly compare the effects of these drugs with those of ICV 5,7-dihydroxytryptamine (5,7-DHT) lesions and to investigate whether 5-HT depletion affects the action of these agents. The effects of M100907 (0, 0.01, 0.03, 0.1 mg/kg IP) and SB 242084 (0, 0.1, 0.25, 0.5 mg/kg IP) were investigated on performance of the 5CSRT in both ICV 5,7-DHT-lesioned and sham-operated rats. RESULTS. ICV 5,7-DHT lesions, which significantly decreased forebrain levels of 5-HT by around 90%, increased levels of premature responding, decreased omissions and the latency to respond correctly, yet did not affect performance accuracy. M100907 decreased premature responding in sham-operated controls but not in 5-HT...Continue Reading

References

Aug 1, 1972·Experimental Neurology·B Jones, M Mishkin
Dec 1, 1980·Journal of Neuroscience Methods·G PaxinosP C Emson
Aug 1, 1993·Acta Physiologica Scandinavica·L ArboreliusT H Svensson
Apr 1, 1997·Neuropharmacology·G A KennettT P Blackburn
Aug 26, 1999·Neuropharmacology·N M Barnes, T Sharp
Jul 11, 2000·Journal of Psychopharmacology·E Hollander, J Rosen
May 8, 2001·Trends in Pharmacological Sciences·V Di MatteoE Esposito
May 15, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffrey W DalleyTrevor W Robbins
Mar 26, 2003·Life Sciences·Dirk Van OekelenJosée E Leysen
Jun 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jennifer McDonaldHarriet de Wit
Apr 1, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Catharine A WinstanleyTrevor W Robbins

❮ Previous
Next ❯

Citations

Oct 20, 2009·Psychopharmacology·Valerie VoonMark Hallett
Dec 3, 2011·Psychopharmacology·Petra J J Baarendse, Louk J M J Vanderschuren
Nov 15, 2011·Molecular Neurobiology·M Victoria Puig, Allan T Gulledge
Jan 21, 2012·Molecular Neurobiology·Katsuhiko MiyazakiKenji Doya
Jul 16, 2013·Neuropharmacology·Kathryn A Cunningham, Noelle C Anastasio
Oct 29, 2008·Psychological Bulletin·Melissa A Cyders, Gregory T Smith
Aug 15, 2012·Behavioral Neuroscience·Tamara L Doremus-FitzwaterLinda P Spear
Nov 14, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Dawn M EagleTrevor W Robbins
Nov 27, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Naomi A FinebergEric Hollander
Jan 15, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Eduardo A SchilmanDaphna Joel
Mar 27, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Adam L HalberstadtSusan B Powell
Oct 1, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Y-Lan Boureau, Peter Dayan
Sep 17, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stan B Floresco, James D Jentsch
Oct 1, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert D Rogers
Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Boris B QuednowFranz X Vollenweider
Jul 6, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yann PellouxBarry J Everitt
Jan 11, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Luis PennanenLaurence H Tecott
May 10, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Trevor HumbyLawrence S Wilkinson
Aug 14, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Noelle C AnastasioKathryn A Cunningham
Sep 30, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mirjana CarliClaudia Balducci
Oct 25, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Vasileios BoulougourisTrevor W Robbins
Nov 30, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Emma S J RobinsonTrevor W Robbins
May 23, 2012·Cerebral Cortex·Andrew R AbelaY Chudasama
Jan 25, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Noelle C AnastasioKathryn A Cunningham
Sep 3, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Deepika SuriMark S Ansorge
Jan 28, 2014·Psychopharmacology·Jessica J Stanis, Susan L Andersen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.